Evaluating the Impact of Programmatic Mass Drug Administration for Malaria in Zambia Using Routine Incidence Data.
impact evaluation
malaria
mass drug administration
routine data
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
19 04 2022
19 04 2022
Historique:
received:
21
04
2020
accepted:
17
07
2020
pubmed:
22
7
2020
medline:
21
4
2022
entrez:
22
7
2020
Statut:
ppublish
Résumé
In 2016, the Zambian National Malaria Elimination Centre started programmatic mass drug administration (pMDA) campaigns with dihydroartemisinin-piperaquine as a malaria elimination tool in Southern Province. Two rounds were administered, 2 months apart (coverage 70% and 57%, respectively). We evaluated the impact of 1 year of pMDA on malaria incidence using routine data. We conducted an interrupted time series with comparison group analysis on monthly incidence data collected at the health facility catchment area (HFCA) level, with a negative binomial model using generalized estimating equations. Programmatic mass drug administration was conducted in HFCAs with greater than 50 cases/1000 people per year. Ten HFCAs with incidence rates marginally above this threshold (pMDA group) were compared with 20 HFCAs marginally below (comparison group). The pMDA HFCAs saw a 46% greater decrease in incidence at the time of intervention than the comparison areas (incidence rate ratio = 0.536; confidence interval = 0.337-0.852); however, incidence increased toward the end of the season. No HFCAs saw a transmission interruption. Programmatic mass drug administration, implemented during 1 year with imperfect coverage in low transmission areas with suboptimal vector control coverage, significantly reduced incidence. However, elimination will require additional tools. Routine data are important resources for programmatic impact evaluations and should be considered for future analyses.
Sections du résumé
BACKGROUND
In 2016, the Zambian National Malaria Elimination Centre started programmatic mass drug administration (pMDA) campaigns with dihydroartemisinin-piperaquine as a malaria elimination tool in Southern Province. Two rounds were administered, 2 months apart (coverage 70% and 57%, respectively). We evaluated the impact of 1 year of pMDA on malaria incidence using routine data.
METHODS
We conducted an interrupted time series with comparison group analysis on monthly incidence data collected at the health facility catchment area (HFCA) level, with a negative binomial model using generalized estimating equations. Programmatic mass drug administration was conducted in HFCAs with greater than 50 cases/1000 people per year. Ten HFCAs with incidence rates marginally above this threshold (pMDA group) were compared with 20 HFCAs marginally below (comparison group).
RESULTS
The pMDA HFCAs saw a 46% greater decrease in incidence at the time of intervention than the comparison areas (incidence rate ratio = 0.536; confidence interval = 0.337-0.852); however, incidence increased toward the end of the season. No HFCAs saw a transmission interruption.
CONCLUSIONS
Programmatic mass drug administration, implemented during 1 year with imperfect coverage in low transmission areas with suboptimal vector control coverage, significantly reduced incidence. However, elimination will require additional tools. Routine data are important resources for programmatic impact evaluations and should be considered for future analyses.
Identifiants
pubmed: 32691047
pii: 5874132
doi: 10.1093/infdis/jiaa434
pmc: PMC9016426
doi:
Substances chimiques
Antimalarials
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1415-1423Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Am J Trop Med Hyg. 2020 Aug;103(2_Suppl):74-81
pubmed: 32618250
Malar J. 2018 Nov 3;17(1):405
pubmed: 30390647
Drugs. 2012 May 7;72(7):937-61
pubmed: 22515619
J Infect Dis. 2016 Dec 15;214(12):1831-1839
pubmed: 27923947
Elife. 2015 Dec 29;4:
pubmed: 26714109
Clin Infect Dis. 2018 Aug 31;67(6):817-826
pubmed: 29522113
Am J Trop Med Hyg. 2020 Aug;103(2_Suppl):7-18
pubmed: 32618247
Parasit Vectors. 2018 Jan 30;11(1):71
pubmed: 29382388
Malar J. 2016 Sep 20;15:480
pubmed: 27646649
Malar J. 2019 Aug 22;18(1):281
pubmed: 31438950
Am J Trop Med Hyg. 2017 Sep;97(3_Suppl):46-57
pubmed: 28990915
Wellcome Open Res. 2017 Sep 6;2:81
pubmed: 29062913
BMC Med. 2018 Dec 10;16(1):215
pubmed: 30526588
Am J Trop Med Hyg. 2015 Jul;93(1):125-134
pubmed: 26013371